Mag3 Technescan (Betiatide)

Betiatide is a synthetic peptide whose exact biological target has not been publicly disclosed. Preliminary research suggests it may influence cellular signaling pathways, but the definitive mechanism of action remains under investigation and is not yet defined in regulatory filings.

The dosing regimen for Betiatide is determined by the treating physician based on the specific clinical trial protocol or investigational use. No standardized dose is publicly available, and the prescriber sets the appropriate amount for each patient.

Safety data for Betiatide in pregnant or lactating individuals are insufficient. Because the drug is still investigational, it is generally advised to avoid use during pregnancy and breastfeeding unless the potential benefit justifies the potential risk and a specialist is consulted.

To request Mag3 Technescan, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Betiatide is a peptide under clinical evaluation, similar to other investigational agents that target cellular pathways. Compared with alternatives, its unique sequence and proposed mechanism are distinct, but direct efficacy or safety comparisons are not possible until head‑to‑head clinical data become available.

Mag3 Technescan should be stored at 2‑8 °C, protected from light, and kept in its original packaging. The product must not be frozen or shaken, and any unused portion should be discarded according to local regulations after the recommended storage period.

Mag3 Technescan is administered intravenously by a qualified healthcare professional. The infusion is given under controlled conditions, typically using a sterile infusion set, and the patient is monitored for any immediate reactions during and after the administration.

The most serious potential risks include rare hypersensitivity or allergic reactions that may manifest as rash, difficulty breathing, or anaphylaxis. Because clinical data are limited, any unexpected severe adverse events should be reported promptly to the overseeing clinical team.

Patients with known hypersensitivity to Betiatide or any excipients in the formulation should not receive the product. Additionally, it is contraindicated in pregnant or breastfeeding individuals, and its use is restricted to settings where the benefits outweigh the unknown risks, such as approved clinical trials.